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Abstract
Background: Significantly increased rate of hospitalizations in current smokers is a major 
smoking-related problem which is associated with a heavy economic burden, whereas car-
diovascular disease accounted for nearly half of hospitalizations. The effect of bezafibrate on 
the rate of re-hospitalization in smokers already treated with statin immediately post-acute 
coronary syndrome (ACS) is unknown. The aim of this study was to investigate 30-day rate of 
re-hospitalization in current smokers participating in the ACS Israeli Surveys (ACSIS) and 
who were treated on discharge with a bezafibrate/statin combination vs. statin alone.
Methods: The study population comprised 3392 patients with confirmed current smoking 
status from the ACSIS 2000, 2002, 2004, 2006, 2008 and 2010 enrollment waves who were 
alive on discharge and received statin. Of these, 3189 (94%) were discharged with statin alone, 
203 (6%) with a combination of a statin and bezafibrate.
Results: Thirty-day re-hospitalization rate was significantly lower in patients from the com-
bination group than in their counterparts from the statin monotherapy group: 12.8% vs. 19%, 
p = 0.028. Multivariable analysis identified the combined bezafibrate/statin treatment as an 
independent predictor of reduced risk of 30-day re-hospitalization rate with odds ratio (OR) 
0.53 (95% confidence interval [CI] 0.31–0.91), and it corresponded to 47% risk reduction. 
Other significant variables in our model associated with independent risk of 30-day re-hospi-
talization rate during the follow-up were female gender (OR 1.43, CI 1.05–1.95, p = 0.03) and 
age > 65 years (OR 1.49, CI 1.13–1.95, p = 0.004).
Conclusions: Adding bezafibrate to statin in smokers was associated with a significantly 
reduced 30-day rate of re-hospitalization after ACS. (Cardiol J 2014; 21, 4: 364–369)
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Introduction
Tobacco use is a principal contributor to the 
development of coronary artery disease (CAD) and 
its consequences, including sudden cardiac death, 
acute myocardial infarction (MI), heart failure and 
increased rate of hospitalizations. Significantly 
increased rate of hospitalizations in current smok-
ers is a major smoking-related problem which is 
associated with heavy economic burden, whereas 
cardiovascular disease (CVD) accounted for nearly 
half of hospitalizations [1–3].
Smoking leads to oxidative stress, a hyper-
coagulable and pro-inflammatory states which are 
strongly associated with atherothrombosis and 
CAD [4–10]. In the INTERHEART study, tobacco 
use was associated with a 3-fold increase in the 
risk for nonfatal acute MI [2]. The relationship 
was dose-dependent, which showed that those 
who smoked a pack per day or more had a 4.6-fold 
increase in the risk compared to non-smokers [3].
Bezafibrate is a pharmacological ligand of 
all peroxisome proliferators-activated receptors 
(PPARs) with ability to increase high density 
lipoprotein-cholesterol (HDL-C) and decrease 
triglyceride, glucose and fibrinogen concentrations 
[11–19]. The effect of bezafibrate on the rate of 
re-hospitalizations in smokers already treated by 
statin immediately post-acute coronary syndrome 
(ACS) is unknown.
The main aim of this study was to investigate 
30-day rate of re-hospitalization in current smokers 
participating in the ACS Israeli Surveys (ACSIS) 
who were treated on discharge with a bezafibrate/ 
/statin combination vs. statin alone. In addition, 
30-day rate of major adverse cardiovascular events 
(MACE) and 1-year mortality rate was also evalu-
ated.
Methods
Study population
Our patients have been drawn from the ACSIS 
2000, 2002, 2004, 2006, 2008 and 2010 enrollment 
waves. Details of the ACSIS Registry have been 
previously reported [20].
In brief, the ACSIS Registry is a 2-month 
nationwide survey conducted biennially that pro-
spectively collects data from all ACS admissions in 
all 25 coronary care units (CCU) in Israel. Patient 
management was at the discretion of the attending 
physicians. Eligibility for the study was validated 
before discharge from the CCU. Discharge diagno-
ses were recorded as determined by the attending 
physicians based on clinical, electrocardiographic, 
and enzymatic criteria. Demographic, historical 
and clinical data, including medical management, 
were recorded on pre-specified forms by dedicated 
study physicians. The Central Data Coordinating 
Center (based at the Sheba Medical Center) was re-
sponsible for the collection of all case report forms 
and the Israel Heart Society was responsible for 
keeping the survey database. Thirty-day outcome 
rates and 1-year mortality rate were ascertained by 
hospital chart review, telephone contact and use of 
the Israeli National Population Registry.
Our study population comprised 3392 patients 
who met the following criteria: were alive on dis-
charge from the hospital, received statin, 30-day 
MACE rate was available, bezafibrate treatment on 
discharge was recorded, current smoking status 
— as registered on hospital admission. Of these, 
3189 (94%) were discharged with statin alone, 203 
(6%) with a combination of a statin and bezafibrate.
Ethics statement
This register-based analysis of pre-existing 
data was conducted according to the principles 
expressed in the Declaration of Helsinki. The 
ACSIS was approved by the ethics committee of 
the Sheba Medical Center. All patients provided 
written informed consent for the collection of data 
and subsequent analysis.
Endpoints and definitions
In our study we used pre-specified definitions 
of the ACSIS. The diagnosis of diabetes was done 
by the attending physician based on the reported 
history, medical records and/or for patients with 
fasting blood glucose of ≥ 126 mg/dL (7 mmol/L) 
registered twice or taking any type of pharmaco-
logic anti-diabetic treatment prior to enrollment. 
Smoking habits were determined on the basis of 
self-reporting by the patients during interviews 
held with study physicians. The diagnosis of 
hypertension was done based on the reported 
history, medical records and/or for patients with 
blood pressure > 140/90 mm Hg registered twice, 
or treatment with antihypertensive drugs prior to 
enrollment.
The primary endpoint of our study was 30-day 
re-hospitalization rate. Secondary endpoints were 
30-day MACE rate (which was defined as a compo-
site measure of 30-day all-cause mortality, recurrent 
MI, recurrent ischemia, stent thrombosis, ischemic 
stroke and urgent revascularization) and 1-year 
all-cause mortality.
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Statistical analysis
Statistical analysis was performed using SPSS 
statistical software. Categorical variables were ex-
pressed as percentages, and continuous variables 
were expressed as mean ± standard deviation. 
Comparisons of variables were performed by c2 
and Fisher’s exact test for categorical variables and 
by unpaired ANOVA test for continuous variables. 
Survival curves were derived using the Kaplan-
-Meier approach, and unadjusted comparisons of 
survival curves were performed using the log-rank 
test.
In order to determine whether the combina-
tion of bezafibrate and statin vs. statin only treat-
ment on discharge is an independent explanatory 
variable for re-hospitalization rate, multivariable 
logistic regression analysis was applied with ad-
justment for the following variables: age, gender, 
hypertension, diastolic blood pressure, diabetes, 
performing of the coronary angiography and per-
cutaneous coronary intervention.
Results are presented as odds ratio (OR) with 
the appropriate 95% confidence interval (CI). All 
tests were 2-sided and p value < 0.05 was consi-
dered statistically significant.
Results
Our population was categorized into 2 groups: 
1) patients receiving on discharge statin monothera-
py — 3189; and 2) patients receiving on discharge 
a combined bezafibrate/statin treatment — 203.
Baseline data
The main clinical and laboratory character-
istics of patients are presented in Tables 1 and 2. 
The majority of patients in both groups were men. Pa-
tients receiving bezafibrate were younger (52.47 ± 
± 9.731 vs. 55.84 ± 10.3 years). On the other hand, 
Table 1. Baseline characteristics and co-morbidities of the study population.
Characteristics Statin alone (n = 3189) Bezafibrate/Statin (n = 203) P
Age [years] 55.8 ± 10.3 52.5 ± 9.7 < 0.0001
Body mass index [kg/m2] 27.1 ± 4.2 29.3 ± 4.4 < 0.0001
Weight [kg] 80.2 ± 14.5 86.7 ± 15.5 < 0.0001
Women 352 (11%) 25 (12.3%) 0.567
Hypertension 1333 (41.8%) 116 (57.1%) < 0.0001
Diabetes 786 (24.6%) 80 (39.4%) < 0.0001
History of stroke 169 (5.3%) 13 (6.4%) 0.498
Chronic renal failure 144 (4.5%) 9 (4.4%) 0.956
Peripheral vascular disease 258 (8.1%) 11 (5.4%) 0.172
Data are number (%) of patients or mean ± standard deviation.
Table 2. In-hospital cardiac interventions and laboratory values.
Characteristics Statin alone (n = 3189) Bezafibrate/Statin (n = 203) P
Coronary artery bypass graft 131/3189 (4.1%) 7/203 (3.4%) 0.645
Percutaneous coronary intervention 1394/2866 (48.6%) 105/177 (59.3%) 0.006
Only angiography 398/2778 (14.3%) 36/179 (20.1%) 0.034
Systolic blood pressure [mm Hg] 139.07 ± 27.725 142.16 ± 24.179 0.122
Diastolic blood pressure [mm Hg] 82.25 ± 16.979 84.92 ± 15.740 0.030
Heart rate [bpm] 79.58 ± 18.980 80.05 ± 14.924 0.727
Glucose [mg/dL] 140.30 ± 67.184 155.00 ± 77.210 0.008
Total cholesterol [mg/dL] 197.78 ± 45.992 213.64 ± 48.884 < 0.0001
HDL-cholesterol [mg/dL] 39.02 ± 11.716 32.86 ± 6.979 < 0.0001
LDL-cholesterol [mg/dL] 122.00 ± 38.677 118.30 ± 43.048 0.287
Triglycerides [mg/dL] 170.38 ± 110.829 396.182 ± 80.008 < 0.0001
Creatinine [mg/dL] 1.05 ± 0.591 1.03 ± 0.384 0.523
Data are number of patients/number of interventions/(%) for interventions or mean ± standard deviation for laboratory values.
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they had appreciably more co-morbidities (hyper-
tension and diabetes) and unfavorable cardio-me-
tabolic profile (as regards glucose, total cholesterol, 
triglyceride and HDL-C levels). Weight, body mass 
index and diastolic blood pressure were also sig-
nificantly higher in patients receiving bezafibrate.
No significant differences between the groups 
were found for history of stroke, chronic renal 
failure and peripheral vascular disease. In patients 
receiving bezafibrate were performed more in-
hospital coronary angiographies and percutaneous 
coronary interventions.
Data regarding treatment with cardiovascular 
drugs among the study groups are presented in Ta-
ble 3. Antiplatelet drugs (aspirin and clopidogrel), 
beta-blockers and angiotensin converting enzyme 
inhibitors were the most commonly used medica-
tions. The use of nitrates, calcium antagonists and 
diuretics was relatively low.
More patients from the combination bezafi-
brate/statin group received beta-blockers and 
insulin than their counterparts. There were no 
significant differences in the proportion of patients 
receiving other cardiovascular drugs.
Outcomes of the study population  
during follow-up
During the follow-up period of 30 days, deve-
lopment of MACE was recorded in 343 patients: 
in 328 (10.3%) of patients from the statin mono-
therapy group vs. 15 (7.4%) from the combined 
bezafibrate/statin group (p = 0.19) (Table 4).
Thirty-day re-hospitalization rate was sig-
nificantly lower in patients from the combination 
group than in their counterparts from the statin 
monotherapy group: 12.8% vs. 19% (p = 0.028).
Crude 1-year mortality rates in patients of the 
combination bezafibrate/statin group tended to be 
lower than in their counterparts of the statin mono-
therapy group (2.5% vs. 3.2%), but this trend did not 
reach statistical significance. Kaplan-Meier analysis 
showed that the cumulative probability of survival 
at 1-year of follow-up (in accordance with the time 
of occurrence) was numerically higher among pa-
tients who received combined bezafibrate/statin 
therapy compared with patients who received statin 
monotherapy. However, possibly due to sample size 
limitations and relatively low number of mortality 
events, this trend was statistically non-significant.
Table 4. Outcomes of the study population during the follow-up (crude data).
Outcomes Statin alone  
(n = 3189)
Fibrate/Statin  
(n = 203)
P
30-day MACE 328 (10.3%) 15 (7.4%) 0.187
30-day re-hospitalization 606 (19%) 26 (12.8%) 0.028
1-year all-cause mortality 105 (3.3%) 5 (2.5%) 0.527
Data are number of events/(%). The primary endpoints of this study were a) 30-day major adverse coronary events (MACE): all-cause  
mortality, recurrent myocardial infarction, recurrent ischemia, stent thrombosis, ischemic stroke, urgent revascularization during follow-up;  
b) 30-day re-hospitalization rate.
Table 3. Distribution of cardiovascular drugs among the study patients (on discharge).
Drugs Statin alone  
(n = 3189)
Bezafibrate/Statin  
(n = 203)
P
Aspirin 97.7% 97.1% 0.60
Clopidogrel 76.9% 76.1% 0.77
Beta-blockers 82.4% 90.0% 0.004
Nitrates 13.4% 9.1% 0.11
Calcium channel blockers 11.2% 11.4% 0.18
Diuretics 12.2% 11.4% 0.75
Aldosterone antagonist 4.4% 7.5% 0.06
Angiotensin converting enzyme inhibitors 71.2% 73.3% 0.51
Angiotenesin receptor blockers 4.3% 7.9% 0.14
Insulin 4.8% 10.0% < 0.001
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Multivariable analysis identified the combined 
bezafibrate/statin treatment as an independent pre-
dictor of reduced risk of 30-day re-hospitalization 
rate with OR 0.53, 95% CI 0.31–0.91, correspond-
ing to 47% risk reduction. Other significant vari-
ables in our model associated with independent risk 
of 30-day re-hospitalization rate during follow-up 
were female gender (OR 1.43, 95% CI 1.05–1.95, 
p = 0.03) and age > 65 years (OR 1.49, 95% CI 
1.13–1.95, p = 0.004).
Discussion
The main finding of our study is a significant 
association between addition of bezafibrate to statin 
in smokers after ACS and reduced 30-day rate of 
re-hospitalization.
Also 30-day MACE and 1-year mortality rates 
were numerically lower among patients who re-
ceived combined bezafibrate/statin therapy com-
pared with patients who received statin mono-
therapy. However, possibly due to sample size 
limitations and relatively low number of mortality 
events, this trend was statistically non-significant. 
Smoking status is strongly associated with admis-
sions and duration of hospitalizations with large 
healthcare expenditures. A number of studies have 
found smoking to be associated with more hospital 
days and an increased utilization of hospital ser-
vices [21–24], whereas CVD accounted for near 
half of hospitalizations [1, 25].
The economic consequences of tobacco use 
are both direct in the form of higher health care 
costs and transportation to and from health care fa-
cility, and indirect costs in the form of productivity 
losses due to morbidity and premature mortality.
Growing evidence supports the hypothesis 
that oxidative stress, glucose metabolism status, 
a hyper-coagulable and pro-inflammatory state, 
leading to atherothrombosis, provide a pathophysi-
ological link between cigarette smoking and CAD 
[26–29]. Levels of circulating fibrinogen, one of 
the strongest predictors of coronary events, are in-
creased in smokers [10, 28]. Smoking may also en-
hance circulating levels of inflammation-associated 
factors such as the acute phase proteins-C-reactive 
protein (CRP), serum amyloid A, complement 
proteins, interleukins (IL): IL-6, IL-2, IL-18, and 
tumor necrosis factor alpha (TNF-a) [7, 26].
Bezafibrate is a pharmacological ligand of all 
PPARs with ability to decrease triglyceride, glu-
cose levels, insulin resistance and increase HDL-C 
[11–13]. In addition, bezafibrate has important fi-
brinogen-related properties and anti-inflammatory 
effects: it lowers fibrinogen concentrations and 
reduces other markers of systemic inflammation 
like TNF-a, IL-6 and CRP [14–19]. Therefore, 
a significant association between bezafibrate treat-
ment and reduced 30-day rate of re-hospitalizations 
in smokers after ACS is biologically plausible.
Limitations of the study
Our analysis was not a randomized controlled 
trial and we cannot rule out other factors that could 
have influenced the observed improvements in 
clinical outcomes. Number of patients received 
statin and bezafibrate combination was relatively 
small compared to the group of statin alone. There-
fore, caution should be taken in using our findings 
which require further confirmation in a prospective 
controlled clinical trial.
Conclusions
In conclusion, adding bezafibrate to statin in 
smokers was associated with a significantly re-
duced 30-day rate of re-hospitalization after ACS.
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